Roquefort Therapeutics Company Description

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer.

Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action.

The company was incorporated in 2020 and is based in London, the United Kingdom.

Roquefort Therapeutics plc

Country	United Kingdom
Founded	2020
Industry	Biotechnology
Sector	Healthcare
Employees	10
CEO	Trevor Reginald

Contact Details

Address: 85 Great Portland Street London, W1W 7LT United Kingdom
Phone	44 20 3918 8633
Website	roquefortplc.com

Stock Details

Ticker Symbol	ROQ
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB00BMDQ2T15
SIC Code	6726

Key Executives

Name	Position
Trevor Ajanthan Reginald	Chief Executive Officer and Executive Director
Stephen Paul West B.Com, CA	Executive Chairman
Dr. Emma Morris	Head of Pre-Clinical Research